Results 81 to 90 of about 21,933 (136)

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients [PDF]

, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core   +1 more source

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Advances in Hematology, 2010
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi, D. C. Nanho, E. N'dathz, P. Kouehion, R. Dissieka, A. Attia, K. Mozard, A. Tolo, K. Boidy, N. Meité, R. Ayemou, M. Sekongo, N. Tea, I. Sanogo   +13 more
doaj   +1 more source

Effective treatment of hypereosinophilic syndrome with imatinib mesylate [PDF]

, 2019
Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilicsyndrome (HES).
Chami, Beatrice, Bitar, Nizar, kadri, Adel, Bazarbachi, Ali, Salem, Ziad, Chehali, Aref, Zalloua, Pierre A., Abboud, Miguel   +7 more
core   +1 more source

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia

Eurasian Journal of Medicine, 2011
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak, Harika Celebi, Aynur Albayrak, Esra Saribacak Can, Vedat Aslan, Birgul Onec, Ipek Coban   +6 more
doaj  

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

Case Reports in Oncological Medicine, 2011
Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka, Masahiro Takahashi, Hiroshi Nanjo, Hideaki Miyazawa, Masatake Iida, Yuki Abe, Mario Jin, Hirohide Onishi, Manabu Hashimoto, Yuzo Yamamoto, Hiroyuki Shibata   +10 more
doaj   +1 more source

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

Turkish Journal of Hematology, 2016
INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay, Fezan Şahin Mutlu, Zafer Gülbaş   +2 more
doaj   +1 more source

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation [PDF]

, 2012
The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP).
Flis, Krzysztof, Skorski, Tomasz, Bhatia, Ravi, Irvine, David, Bhatia, R., Copland, Mhairi, Irvine, D., Copland, M., Skorski, T., Flis, K.   +9 more
core   +1 more source

Is imatinib mesylate a promising drug in systemic sclerosis?

, 2008
A patient with therapy-resistant and progressive systemic sclerosis (SSc) with pulmonary involvement who was treated with imatinib mesylate is described herein. Prior to treatment.
Dik, Wim, van Daele, Paul, Thio, Bing, van Hagen, P.M., Hal, PTW, Hooijkaas, H (Herbert), van Laar, Jan, van Daele, Paul; id_orcid   +7 more
core   +2 more sources

Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia. [PDF]

, 2010
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core  

Imatinib mesylate in the treatment of gastrointestinal stromal tumour

, 2005
Imatinib mesylate is a selective and potent small-molecule inhibitor of tyrosine kinases, including Kit, platelet-derived growth factor receptor, and the BCR-Abl fusion protein.
Steinert, Dejka M, McAuliffe, John C, Trent, Jonathan C   +2 more
core   +1 more source